B-cell Malignancy Clinical Trial
Official title:
An Open and Single Dose-escalation Study to Evaluate the Safety and Clinical Activity of Allogeneic CAR-T Targeting CD22(ThisCART22) in Patients With Relapsed and/or Refractory Non-Hodgkin's B Cell Lymphoma (r/r B-NHL)
A single arm, open-label, dose-escalation study to evaluate the safety and clinical activity of ThisCART22 (Allogeneic CAR-T targeting CD22) in patients with relapsed and/or refractory non-Hodgkin's B cell lymphoma (r/r B-NHL).
ThisCART22 cell is a non-gene-editing allogeneic CAR-T cell targeting CD22. This study is designed to evaluate the safety and clinical activity of ThisCART22 in patients with CD22 positive, relapsed and/or refractory non-Hodgkin's B cell lymphoma (r/r B-NHL). ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT05006716 -
A Dose-Escalation and Expansion Study of BGB-16673 in Participants With B-Cell Malignancies
|
Phase 1/Phase 2 | |
| Recruiting |
NCT05106907 -
Safety and Clinical Activity of ThisCART19 in Patients With r/r Non-Hodgkin's B Cell Lymphoma
|
Phase 1 | |
| Recruiting |
NCT05294731 -
Treatment of Chinese Participants With B-Cell Malignancies With BGB-16673, a Bruton Tyrosine Kinase-Targeted Protein-Degrader
|
Phase 1/Phase 2 | |
| Recruiting |
NCT05643742 -
A Safety and Efficacy Study Evaluating CTX112 in Subjects With Relapsed or Refractory B-Cell Malignancies
|
Phase 1/Phase 2 | |
| Active, not recruiting |
NCT04035434 -
A Safety and Efficacy Study Evaluating CTX110 in Subjects With Relapsed or Refractory B-Cell Malignancies (CARBON)
|
Phase 1/Phase 2 | |
| Recruiting |
NCT05602363 -
AS-1763 in Patients With Previously Treated CLL/SLL or Non-Hodgkin Lymphoma
|
Phase 1 | |
| Completed |
NCT03952923 -
CD19-CAR-T in B-cell Malignancies Patients
|
Phase 1 | |
| Recruiting |
NCT03559439 -
CD19-targeting CAR T Cells in Relapsed or Refractory CD19 Positive B-cell Malignancies
|
Phase 1 |